LABCORP HOLDINGS INC. (LH) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, LABCORP HOLDINGS INC.'s filing signal turned positive.

Labcorp Holdings Inc. is a global life sciences company providing essential laboratory services, operating through two primary segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). In 2025, the company served clients in approximately 100 countries, performing over 750 million tests and supporting over 85% of new drugs approved by the FDA. The Dx segment offers routine and specialty testing across the U.S. and Canada, leveraging a network of over 2,200 patient service centers. The BLS segment provides global drug development support, including central laboratory services for clinical trials, and supported 81% of oncology-related FDA approvals in 2025. The company's strategy focuses on leveraging its scientific and technological strengths to drive growth and differentiate its offerings in the evolving healthcare market.

Revenue is primarily driven by diagnostic testing services for physicians, hospitals, health plans, and patients through its Diagnostics Laboratories segment, and by providing services to pharmaceutical, biotechnology, and diagnostic companies for drug development through its Biopharma Laboratory Services segment.